Pay in 4 interest-free payments of $5.19 Learn more
Ships within 48 hours · Estimated delivery Sep 22 - Sep 27
According to FDA prescribing information, gallbladder-related adverse events occurred in clinical trials of semaglutide for weight management (Wegovy) at rates of 2.5% versus 1.0% with placebo, and for tirzepatide (Zepbound) at rates of 2.5% versus 1.0% with placebo
Oral infections, including thrush or bacterial overgrowth, may become more common due to changes in saliva composition or immune function associated with rapid metabolic changes
Discontinuation rates due to adverse events ranged from 5.3% to 10.3% across orforglipron dose groups, compared to 2.7% in the placebo group
Lancet (London, England), 402(10401), 529544
US$ 27.72
US$ 23.60
US$ 25.41
US$ 29.14
US$ 26.31
US$ 20.37
